Proton beam therapy outcomes for localized unresectable hepatocellular carcinoma
| Autor: | Emma B. Holliday, Bhanu Prasad Venkatesulu, Peter C. Park, Ahmed Kaseb, Evelyne M. Loyer, Yelin Suh, Prajnan Das, Jillian R. Gunther, Sanjay Gupta, Maureen Aliru, Milind Javle, Gabriel O. Sawakuchi, Harmeet Kaur, Bruce D. Minsky, Sam Beddar, Bruno C. Odisio, Sunil Krishnan, Lakshmi Mahadevan, Kanwal Pratap Singh Raghav, Joseph M. Herman, Eugene J. Koay, Cheng-En Hsieh, Christopher H. Crane, Cullen M. Taniguchi, Awalpreet S. Chadha |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2019 |
| Předmět: |
Male
medicine.medical_specialty Carcinoma Hepatocellular ECOG Performance Status Kaplan-Meier Estimate Effective dose (radiation) Article 030218 nuclear medicine & medical imaging 03 medical and health sciences 0302 clinical medicine medicine Dose escalation Proton Therapy Humans Radiology Nuclear Medicine and imaging Four-Dimensional Computed Tomography Aged Prior treatment Aged 80 and over Tumor size Prior Radiotherapy business.industry Radiotherapy Planning Computer-Assisted Disease progression Liver Neoplasms Dose-Response Relationship Radiation Hematology Middle Aged medicine.disease Survival Rate Treatment Outcome Oncology 030220 oncology & carcinogenesis Hepatocellular carcinoma Disease Progression Female Radiology business |
| Popis: | BACKGROUND AND PURPOSE: This study documents the utilization and efficacy of proton beam therapy (PBT) in western patients with localized unresectable hepatocellular carcinoma (HCC). METHODS AND METHODS: Forty-six patients with HCC, Child-Pugh class of A or B, no prior radiotherapy history, and ECOG performance status 0-2 received PBT at our institution from 2007 to 2016. Radiographic control within the PBT field (local control, LC) and overall survival (OS) were calculated from the start of PBT. RESULTS: Most (83%) patients had Child-Pugh class A. Median tumor size was 6 cm (range, 1.5-21.0 cm); 22% of patients had multiple tumors and 28% had tumor vascular thrombosis. Twenty-five (54%) patients received prior treatment. Median biologically effective dose (BED) was 97.7 GyE (range, 33.6-144 GyE) administered in 15 fractions. Actuarial 2-year LC and OS rates were 81% and 62%; median OS was 30.7 months. Out-of-field intrahepatic failure was the most common site of disease progression. Patients receiving BED ≥90 GyE had a significantly better OS than those receiving BED |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|